

REMARKS

Claims 1-26 and 33-38 are pending in this application. The Examiner has required restriction to one of ten groups and corresponding requests for election of species. In response to such restriction and request for species election Applicants wish to proceed as follows.

Restriction Requirement

Applicants elect Group 3 for proceeding with prosecution on the merits. Group 3 contains claims 10-21 and 25, drawn to a composition comprising as active ingredients IL-18 polypeptide or bioactive fragment thereof, and an immunogenic composition comprising an antigen and a saponin containing adjuvant. Claims 20 and 25 have been cancelled.

Election of Species

Applicants elect, as the species of antigen, her-2-neu. Of the elected claims, claims 10-19 and 21 are readable thereon.

Applicants elect, as the species of immunochemical stimulant, 3D-MPL. Of the elected claims, claims 10-19 and 21 are readable thereon.

The Office Action further requests that applicants elect a “single disclosed species of TSLP activity” (see, e.g., middle of page 8 of Office Action). However, as the present claims do not recite “TSLP activity” it is believed this is a typographical error. Clarification by the Examiner is requested.

Co-pending applications

Applicants also bring to the Examiners attention co-pending, commonly owned application U.S. Ser. No. 10/575836 (Docket No. VB60529US).

Conclusion

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

/Virginia G. Campen/
Virginia G. Campen
Attorney for Applicants
Registration No. 37,092

Date: 11 August 2008
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-1012